Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial 90Y-DOTA-TOC for Neuroendocrine Tumor
NCT03197012Phase 1Completed
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of yttrium-90 edotreotide in Neuroendocrine Neoplasm (NEN) (2 arms). Primary endpoints: Overall Response Rate at 36 months and Incidence of Treatment-Related Adverse Events at 36 months. Started Jul 2017; status: completed.
02
Drugs
yttrium-90 edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03197012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197012.